Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded ...
At the state level, legislative momentum is also growing. Several states considering balance billing protections are incorporating provisions requiring state-regulated insurers to cover ...
Early PrimeC treatment slowed functional decline and reduced the risk of death or ALS complications for ALS patients in a ...
As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...
Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic research teams.
4don MSN
Oren Nahari revealed he has ALS: This is the drug given in Israel as compassionate treatment
Veteran journalist Oren Nahari revealed he has ALS, a severe degenerative neurological disease. How many Israelis are diagnosed each year and what are the chances of a cure in the coming years?
Researchers have uncovered a surprising connection between gut bacteria and the development of ALS and frontotemporal dementia. Their work suggests that certain microbes produce inflammatory sugars ...
In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings ...
Spread the loveAs a genetic carrier of a mutation linked to amyotrophic lateral sclerosis (ALS), I find myself in a precarious situation where hope and despair are interwoven. The recent cuts to ...
"Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer ...
A protein tied to ALS and dementia may have a much bigger role in disease than scientists realized. Researchers found that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results